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Abstract
OBJECTIVES—The aim of this study was to assess for a treatment interaction between statin use 
and ET response.
BACKGROUND—Recent data suggest that statins may attenuate exercise training (ET) response, 
but limited data exist in patients with heart failure (HF).
METHODS—HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of 
Exercise Training) was a randomized trial of 2,331 patients with chronic HF with ejection fraction 
≤35% who were randomized to usual care with or without ET. We evaluated whether there was a 
treatment interaction between statins and ET response for the change in quality of life and aerobic 
capacity (peak oxygen consumption and 6-min walk distance) from baseline to 3 months. We also 
assessed for a treatment interaction among atorvastatin, simvastatin, and pravastatin and change in 
these endpoints with ET. Multiple linear regression analyses were performed for each endpoint, 
adjusting for baseline covariates.
RESULTS—Of 2,331 patients in the HF-ACTION trial, 1,353 (58%) were prescribed statins at 
baseline. Patients treated with statins were more likely to be older men with ischemic HF etiology 
but had similar use of renin angiotensin system blockers and beta-blockers. There was no evidence 
of a treatment interaction between statin use and ET on changes in quality of life or exercise 
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capacity, nor was there evidence of differential association between statin type and ET response 
for these endpoints (all p values >0.05).
CONCLUSIONS—In a large chronic HF cohort, there was no evidence of a treatment interaction 
between statin use and short-term change in aerobic capacity and quality of life with ET. These 
findings contrast with recent reports of an attenuation in ET response with statins in a different 
population, highlighting the need for future prospective studies. (Exercise Training Program to 
Improve Clinical Outcomes in Individuals With Congestive Heart Failure; NCT00047437)
Keywords
chronic heart failure; exercise training; heart failure with reduced ejection fraction; statins
In recently updated lipid guidelines, statin use carries a Class I recommendation for 
secondary prevention in patients with atherosclerotic cardiovascular disease and for primary 
prevention in high-risk individuals (1,2). Statin use in heart failure (HF) patients is also 
common. Statin use has a Class III recommendation for patients with HF without other 
indications in the most recent U.S. and European HF guidelines (3–5). However, the most 
common etiology of HF in most developed countries is atherosclerotic cardiovascular 
disease.
Current guidelines recommend nonpharmacological interventions including aerobic exercise 
training (ET) and cardiac rehabilitation (CR) in patients with chronic HF with reduced 
ejection fraction (EF) (4). Although many patients with HF receive statins, and the use of ET 
interventions are increasingly incorporated into a patient-centered treatment approach, 
guidelines do not provide specific recommendations for a combined use strategy or 
appropriate timing for initiating ET and statin therapy (6,7).
Recent data, however, suggest that statins may attenuate the ET response in some 
populations (8). For example, in overweight or obese patients with metabolic risk factors, 
statins attenuated the improvement in muscle enzyme mitochondrial levels and 
cardiorespiratory fitness with ET (8). Consistent with this finding, several small studies have 
also shown statins to reduce skeletal muscle mitochondrial content and oxidative capacity 
(9–12). HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise 
Training) is the largest clinical trial to examine the effect of ET in patients with chronic HF 
receiving contemporary optimal medical therapy (13). We performed a secondary analysis of 
HF-ACTION to assess for a treatment interaction between statin use and response to ET 
with respect to changes in aerobic capacity and health-related quality of life (HR-QoL) from 
baseline to 3 months.
METHODS
HF-ACTION was a multicenter, randomized, placebo-controlled trial of usual care with and 
without an ET regimen in 2,331 patients with stable chronic HF. The study design and 
results have been previously reported (13,14). The ET intervention included 36 supervised 
sessions of aerobic exercise over 3 months, followed by home training on a treadmill or 
stationary cycle for an additional 2 years. The usual care group received self-management 
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educational materials with information on medications, fluid management, and sodium 
intake and recommendations for 30 min of moderate-intensity physical activity most days of 
the week as tolerated. Changes in baseline peak oxygen uptake (VO2) and 6-min walk 
distance (6MWD) were analyzed at 3months to characterize exercise capacity. HR-QoL was 
measured using the 23-item self-administered disease-specific Kansas City Cardiomyopathy 
Questionnaire (KCCQ) at 3 months. Each participating center’s ethics committee or 
institutional reviewboard approved the study, and all patients gave written informed consent. 
The present analysis focuses on patients enrolled in HF-ACTION who were on statin 
therapy at baseline compared with those not on a statin to evaluate for a treatment interaction 
of statin therapy on ET response.
PATIENT POPULATION
Patients enrolled in HF-ACTION were required to have stable chronic HF with left 
ventricular EF ≤35% and New York Heart Association functional class II to IV symptoms 
while on optimal HF therapy for ≥6 weeks. Patients were excluded if they had major 
comorbidities or other limitations that would preclude ET, devices that would prevent 
achievement of target heart rates, or recent (≤6 weeks) or planned (≤6 months) major 
cardiovascular procedures. For the present analysis, statin use was defined as HMG-CoA 
reductase inhibitor use at baseline stratified by the specific statin marked on the case report 
form: atorvastatin, pravastatin, simvastatin, or other. Other lipid-lowering agents were also 
captured.
OUTCOMES OF INTEREST
The primary outcomes for the present analysis were change in peak VO2 and change in 
KCCQ from baseline to 3 months, as in previous HF-ACTION analyses, because of the 
increased missingness at later time points (15,16). The secondary outcome was change in 
6MWD from baseline to 3 months.
STATISTICAL ANALYSIS
We performed post-hoc analyses of patients with and without statin treatment at baseline to 
assess their change in peak VO2, KCCQ, and 6MWD. The baseline characteristics, including 
demographics, physical and laboratory findings, medical history, and therapies, were 
summarized as frequencies and percentages for categorical variables and by medians and 
25th and 75th percentiles for continuous variables in patients stratified by randomized 
treatment (ET vs. usual care) and statin use (no statin vs. statin) (see Table 1). Comparisons 
of baseline characteristics across statin use were conducted within each treatment group 
using Student t tests or Wilcoxon tests for continuous variables and chi-square tests or Fisher 
exact tests for categorical variables when appropriate.
Linear regression models were used in the analysis to examine the relationship between 
statin use and change in the individual endpoints from baseline to 3 months. To account for 
the missing data at 3 months for the outcomes of interest, inverse weighting for missingness 
was performed. Specifically, subjects in the regression model were weighted by the inverse 
of their probability of having a nonmissing response similar to recent analyses in HF-
ACTION (15,16). This should reduce the bias that would have been present in a complete 
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case analysis by assigning higher weight to observed data subjects who were similar to 
subjects who were more likely to have missing data (15). Inverse propensity weighting was 
also used to account for the nonrandom use of statin therapy at baseline (15). The final 
weight used in the analysis is the inverse of the product of the probability for missingness 
and the probability for statin use. To investigate for possible confounding variables, the 
propensity for statin treatment model was selected using backward stepwise variable 
selection methods (conservatively using p < 0.10 to enter and stay in the model) and further 
included all variables previously used in multivariable HF-ACTION models (see Table 2 
footnote) (17). In the weighted linear models, we assessed interactions between randomized 
treatment and statin use for each outcome. From this model, we report the interaction p 
value and adjusted effect estimates for statin use within randomized subgroups.
Analysis of variance was used to examine the relationship between type of statin used and 
the change in exercise capacity and HR-QoL endpoints. Patients were classified into 5 
groups: no statin, atorvastatin, simvastatin, pravastatin, and other. If a significant difference 
in outcomes by statin type was found, multiple comparison (Tukey) analysis was conducted 
to determine what those differences were.
Adherence to ET (defined as exercise >90 min/week for the first 3 months of the study) was 
assessed in the subset of patients randomized to ET comparing statin and nonstatin patients. 
This analysis evaluated for an interaction between statin use and exercise adherence in the 
ET group. These analyses were weighted for missingness and nonrandom statin use and 
adjusted for the same covariates as previously mentioned. Statistical significance was 
assessed using 2-sided p values, with values <0.05 considered statistically significant. All 
statistical computations were generated using SAS version 9.4 (SAS Institute Inc., Cary, 
North Carolina).
RESULTS
Statin therapy was used in 1,353 (58%) patients at baseline in HF-ACTION. The baseline 
characteristics of patients randomized to usual care or ET further dichotomized into those on 
statin therapy versus those not on statins are presented in Table 1. Patients treated with 
statins were more likely to be older men with hypertension, an ischemic etiology of HF, 
peripheral vascular disease, an elevated blood urea nitrogen, and a lower heart rate. 
Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use and beta-blocker 
use were similar between statin and nonstatin patients, whereas mineralocorticoid antagonist 
use was lower and implanted cardioverter-defibrillator use was higher in the statin-treated 
patients.
Patients randomized to usual care had higher rates of missing data compared with those 
randomized to ET at 3 months (Online Table 1). The changes in exercise capacity and HR-
QoL from baseline to 3 months stratified by statin use and randomized treatment group are 
displayed in Tables 2 and 3 (statin type). There was no evidence for a treatment interaction 
between statin use and ET on changes in quality of life or exercise capacity, nor was there 
evidence of differential association between statin type and ET response for the endpoints 
(all p > 0.05). Figure 1 presents statin use and change in Peak VO2, 6MWD, and KCCQ 
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from baseline to 3 months as a function of statin use and ET status. Online Figure 1 displays 
median and interquartile range of the changes in peak VO2, 6MWD, and KCCQ score on the 
basis of type of statin. There was also no interaction between statin use and exercise 
adherence with respect to exercise capacity or HR-QoL in patients randomized to ET 
(interaction p values for peak VO2, 6MWD, and KCCQ of 0.44, 0.80, and 0.60, respectively) 
(Table 4).
DISCUSSION
In the largest clinical trial of ET in patients with chronic HF, we evaluated for a treatment 
interaction between statin use and ET with respect to changes in exercise capacity and HR-
QoL. We found that statin use was more prevalent in older men with hypertension, ischemic 
heart disease, and implanted cardioverter-defibrillators, but these patients had similar use of 
baseline guideline-directed medical therapy for HF compared with nonstatin patients. We 
found no evidence that statin treatment attenuated the response to ET in patients with 
chronic HF and reduced EF. Furthermore, various statins did not have a differential 
association with changes in quality of life or exercise capacity with ET. Our findings suggest 
that patients with HF on statin therapy who undergo ET do not have a blunted training 
response compared with nonstatin patients.
Previous studies suggest that statin use lowers mitochondrial content and oxidative capacity 
(9–12). Furthermore, atorvastatin impairs exercise-mediated mitochondrial adaptations in 
skeletal muscle and lowers running capacity in rodents (18,19). Many highly trained athletes 
are intolerant of statin treatment related to increased muscle enzyme release from skeletal 
muscle after significant endurance events such as marathons (20–23). However, limited data 
exist on changes in aerobic capacity in patients on statin therapy (24). A recent study that 
randomized 37 patients who were overweight or obese and at risk of metabolic syndrome to 
12 weeks of aerobic ET with or without simvastatin demonstrated attenuated 
cardiorespiratory fitness responses and decreased skeletal muscle mitochondrial content in 
patients treated with simvastatin (8). However, 2 small studies evaluated the effects of 40 mg 
daily atorvastatin and 80 mg daily simvastatin in healthy subjects on maximal exercise 
capacity over 8 and 12 weeks of therapy, respectively, demonstrating no effect on maximal 
oxygen consumption (25,26). A prospective study that evaluated 1,201 patients with 
coronary artery disease undergoing 12 weeks of CR after an acute cardiac event found no 
effect of statin therapy on ET response (27). An age/sex-appropriate similar increase in peak 
oxygen consumption from CR in statin and nonstatin treatment was also found (+3.2 ± 3.7 
ml/kg/min and +3.1 ± 3.7 ml/kg/min, respectively) (8,27). The STOMP (Statins on Skeletal 
Muscle Function and Performance) study randomized 420 healthy patients to evaluate 
symptoms, muscle strength, and exercise capacity in patients treated with atorvastatin or 
placebo over 6 months (28). STOMP found that atorvastatin therapy did not decrease 
endurance, aerobic capacity, or physical activity levels compared with placebo (change in 
peak VO2: −0.8 ml/kg/min (−1.3 to −0.3 ml/kg/min )(Post Minus Baseline) and −0.8 
ml/kg/min (−1.4 to −0.2 ml/kg/min)(Post Minus Baseline), respectively) (28). Although 
these studies do not include patients with HF, they include patients who were on potent 
statin therapies for up to 6 months without demonstrating an impaired response to ET. These 
studies support our findings in the chronic HF population. Interesting, a study in rats already 
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undergoing ET that then had statin therapy added also found no attenuated response to 
exercise (29).
In HF-ACTION, ET reduced rehospitalizations and improved quality of life, offering 
significant benefits on top of guideline medical therapy for HF (13, 30, 31). With the recent 
Centers for Medicare and Medicaid expansion of coverage for CR to beneficiaries with HF, 
many patients are being referred for such care, including a sizeable proportion receiving 
statins. Our results suggest that there is no apparent blunting of the response to aerobic ET 
with concomitant statin use. Instead, the expanded CMS coverage for ET should be 
welcomed as a new therapeutic option to improve exercise capacity and quality of life and to 
potentially reduce hospitalizations.
STUDY LIMITATIONS
This was a retrospective analysis from a clinical trial of ET; thus, cause and effect 
relationships for statin therapy cannot be directly assessed. Although several small studies 
have suggested that statin use affects muscle strength, this patient-level data was unavailable 
for analysis in the HF-ACTION trial. Despite covariate adjustment, other measured and 
unmeasured variables may have influenced these results. Overadjustment bias may be 
present, as we do not know the timing of statin initiation relative to variables in the 
propensity model; thus, future prospective studies are needed to externally validate our 
findings. Prior statin use was not captured in the HF-ACTION trial. Thus, if a patient 
discontinued statin therapy due to statin intolerance, whether self-reported or clinically 
confirmed, prior to enrollment in HF-ACTION, they would be included in a nonstatin group 
for the current analysis; this would bias our findings toward the null hypothesis given that up 
to 15% of patients experience statin-related myalgias (32). It is plausible that these patients 
may be more likely to experience attenuated gains in exercise capacity or quality of life in 
response to ET when using statins. The inclusion and exclusion criteria of the HF-ACTION 
trial prevents generalization to the entire HF population, including those with preserved left 
ventricular EF and the very elderly. A final limitation is the modest increase in aerobic 
capacity with ET in HF-ACTION, due in part to low training adherence.
CONCLUSIONS
The results from this retrospective analysis of the large HF-ACTION trial suggest that statin 
therapy does not attenuate the improvement in aerobic capacity or quality of life response to 
ET in patients with chronic HF and reduced EF. Future prospective studies examining the 
effect of statin therapy on the responses to ET in the HF population are warranted to confirm 
our findings.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE
ET and CR carry Class I and IIA recommendations, respectively, in patients with HF, but 
are uncommonly prescribed and completed in patients with HF related to various barriers. 
Our findings suggest that there does not appear to be an attenuated ET response in 
patients with HF on statin therapy.
TRANSLATIONAL OUTLOOK
Statin use does not blunt the ET response in patients with HF and reduced EF who 
engage in ET compared with nonstatin users. Future prospective studies are needed to 
confirm these findings and include patients with HF and preserved EF.
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FIGURE 1. Statin Use and Change in Peak VO2, 6MWD, and KCCQ From Baseline to 3 Months 
as a Function of Statin Use and Exercise Training Status
KCCQ = Kansas City Cardiomyopathy Questionnaire; VO2 = oxygen consumption; 6MWD 
= 6-min walk distance.
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